QNCX Stock Forecast & Price Target

Quince Therapeutics is viewed positively because LAM-001 targets the mTOR-driven vascular remodeling that underlies PH-ILD, potentially offering disease modification rather than the vasodilatory symptom relief seen with approved therapies. The Phase 2a signal was encouraging despite being small and open-label, with improvements in 6MWD, PVR, NT-proBNP, functional class, and lung function, while safety looked favorable with no drug-related SAEs or discontinuations through 24 weeks. The investment case is further supported by a large validated market, expansion optionality in BOS and SAPH, and a strong balance sheet that is expected to fund operations through 2028 and potentially into 2029.

Quince Therapeutics is a high-risk, single-asset story in which most value depends on LAM-001 proving differentiated efficacy in PH-ILD, yet the current dataset is tiny, with key analyses based on only six evaluable patients out of 10, making the signal fragile and hard to generalize. Commercially, the market is attractive but increasingly crowded, as Tyvaso already generated about $1.9B in 2025 sales and competitors like Yutrepia and Insmed’s TPIP are expected to expand the landscape, so LAM-001 must show clear clinical superiority to win adoption. Financially, the company is expected to keep incurring net losses and may need to raise capital, while a failure in the 1Q28 PH-ILD readout could leave shares at or below $3/share with less than $40M in cash.